<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="51.02" right="563.94" top="676.81"><span x0="51.02" y0="676.81" x1="563.94" style="x0: 51.02; x1: 56.58; y0: 676.81; y1: 686.81; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">54.  The G20 HLIP&#8217;s mandate concerns reforms and financing solutions to strengthen preparedness and response to future pandemics. </span><span x0="167.25" y0="663.81" x1="564.25" style="x0: 167.25; x1: 174.84; y0: 663.81; y1: 673.81; width: 7.59; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">However, we must first end this pandemic. We need to take bold, concerted actions to lift the world out of the COVID-19 crisis.</span></div><div left="51.02" right="75.06" top="624.81"><span x0="51.02" y0="624.81" x1="75.06" style="x0: 51.02; x1: 56.58; y0: 624.81; y1: 634.81; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">55.  </span><span x0="72.28" y0="624.81" x1="564.15" style="x0: 72.28; x1: 78.02; y0: 624.81; y1: 634.81; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">The first priority for the international community is to agree on and implement an action plan to vaccinate the majority of the world&#8217;s vulnerable population before the end of 2022. </span></div><div left="72.28" right="564.06" top="585.81"><span x0="72.28" y0="585.81" x1="564.06" style="x0: 72.28; x1: 77.47; y0: 585.81; y1: 595.81; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. Achieving this requires closing the gap in vaccine supply, scaling up delivery capacity across countries to make use of this supply and ensuring that lack of financing is not a binding constraint at any point of this process. </span></div><div left="72.28" right="564.07" top="533.81"><span x0="72.28" y0="533.81" x1="564.07" style="x0: 72.28; x1: 78.39; y0: 533.81; y1: 543.81; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. Despite welcome progress on all fronts, the world is not yet on an assured trajectory to achieve an end to this pandemic by the end of 2022.</span></div><div left="72.28" right="563.97" top="494.81"><span x0="72.28" y0="494.81" x1="563.97" style="x0: 72.28; x1: 77.1; y0: 494.81; y1: 504.81; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">c. The most immediate task is to close the urgent financing gaps for ACT-A and its COVAX Facility for 2021 and 2022. </span></div><div left="72.28" right="563.95" top="455.81"><span x0="72.28" y0="455.81" x1="563.95" style="x0: 72.28; x1: 78.39; y0: 455.81; y1: 465.81; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">d. The IMF has presented a cogent US$50 billion proposal to vaccinate 40% of populations in all countries by end-2021 and 60% by mid-2022, and ensure adequate supply of diagnostics, therapeutics and personal protective equipment (PPE). This will require an urgent combination of grant financing, concessional and non-concessional loans coming from a variety of stakeholders</span><span x0="365.9" y0="421.18" x1="372.4" style="x0: 365.9; x1: 369.14; y0: 421.18; y1: 427.01; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">37</span><span x0="371.91" y0="416.81" x1="374.69" style="x0: 371.91; x1: 374.69; y0: 416.81; y1: 426.81; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">.</span></div><div left="51.02" right="563.95" top="390.81"><span x0="51.02" y0="390.81" x1="563.95" style="x0: 51.02; x1: 56.58; y0: 390.81; y1: 400.81; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">56.  There are now a number of promising proposals on how the required funds can be mobilized and deployed to achieve the goal of global immunization against COVID-19. Among them, the following merit urgent consideration:</span></div><div left="72.28" right="83.05" top="351.81"><span x0="72.28" y0="351.81" x1="83.05" style="x0: 72.28; x1: 77.47; y0: 351.81; y1: 361.81; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. </span><span x0="86.45" y0="351.81" x1="564.22" style="x0: 86.45; x1: 92.93; y0: 351.81; y1: 361.81; width: 6.48; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Raising additional grant financing is the most appropriate way to support LIC access to vaccines and other medical countermeasures, as well as global public goods like surveillance and research</span><span x0="551.72" y0="343.18" x1="558.36" style="x0: 551.72; x1: 554.96; y0: 343.18; y1: 349.01; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">38</span><span x0="558.48" y0="338.81" x1="564.04" style="x0: 558.48; x1: 561.26; y0: 338.81; y1: 348.81; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. However, relying on ad hoc bilateral contributions &#8212; as we have done for the last year and a half &#8212; has still left a large gap to be closed. Recent additional commitments from the G7 countries as well as the efforts of Norway and South Africa, Co-Chairs of the ACT-A Facilitation Council, to build support for equitable burden-sharing amongst countries, now need to be accelerated and followed through from commitment to disbursement.</span></div><div left="72.29" right="320.32" top="247.81"><span x0="72.29" y0="247.81" x1="320.32" style="x0: 72.29; x1: 78.4; y0: 247.81; y1: 257.81; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. In parallel to efforts to mobilize additional grants, </span><span x0="320.41" y0="247.81" x1="564.13" style="x0: 320.41; x1: 325.78; y0: 247.81; y1: 257.81; width: 5.37; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">LICs and MICs should be able to acquire vaccines and other resources by drawing on concessional finance from the International Financial Institutions (IFIs). </span><span x0="115.67" y0="221.81" x1="564.09" style="x0: 115.67; x1: 121.97; y0: 221.81; y1: 231.81; width: 6.3; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">Borrowing from existing or new IFI facilities should be seen as a second-best alternative to grant funding; however, rapid access to concessional loans is far better than delaying vaccine purchases and vaccination drives until sufficient grants have been mobilized. </span></div><div left="86.46" right="564.06" top="169.81"><span x0="86.46" y0="169.81" x1="564.06" style="x0: 86.46; x1: 88.86; y0: 169.81; y1: 179.81; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. Existing vaccine financing windows in the MDBs need to be expanded and streamlined to disburse funds more expeditiously and through upfront bridge finance, in coordination with ACT-A and the COVAX Facility. </span></div><div left="51.02" right="55.57" top="94.33"><span x0="51.02" y0="94.33" x1="55.57" style="x0: 51.02; x1: 53.29; y0: 94.33; y1: 98.42; width: 2.27; font-size: 4.08; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">37</span><span x0="58.11" y0="91.27" x1="487.66" style="x0: 58.11; x1: 62.0; y0: 91.27; y1: 98.27; width: 3.89; font-size: 7.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">https://www.imf.org/en/Publications/Staff-Discussion-Notes/Issues/2021/05/19/A-Proposal-to-End-the-COVID-19-Pandemic-460263</span></div><div left="51.02" right="55.67" top="83.1"><span x0="51.02" y0="83.1" x1="55.67" style="x0: 51.02; x1: 53.29; y0: 83.1; y1: 87.18; width: 2.27; font-size: 4.08; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">38</span><span x0="58.11" y0="80.04" x1="563.25" style="x0: 58.11; x1: 63.04; y0: 80.04; y1: 87.04; width: 4.93; font-size: 7.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">Agarwal and Reed (2021) suggest that besides an upfront grant of US$4b to the COVAX AMC, there are two additional options to address the funding gap that rely on the existing institutional framework:</span></div><div left="51.02" right="349.15" top="740.84"><span x0="51.02" y0="740.84" x1="349.15" style="x0: 51.02; x1: 71.57; y0: 740.84; y1: 770.84; width: 20.55; font-size: 30.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Heavy;">C. Financing Priorities</span></div><div left="51.02" right="506.94" top="710.22"><span x0="51.02" y0="710.22" x1="506.94" style="x0: 51.02; x1: 62.5; y0: 710.22; y1: 730.22; width: 11.48; font-size: 20.0; fill: [0, 0.549, 0.815]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Heavy;">The Immediate Task: Funding ACT-A and COVAX</span></div></body></html>